European Neuropsychopharmacology

Papers
(The H4-Index of European Neuropsychopharmacology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
T58. EXPLORATION OF GENETIC AND CLINICAL HETEROGENEITY IN AUTISM BY CLUSTERING GENES BASED ON BULK AND SINGLE-CELL TRANSCRIPTOMIC DATA394
11. ESTABLISHING THE MOLECULAR FOUNDATION OF BRAIN ANATOMY IN LIVING INDIVIDUALS110
T47. A MULTI-OMIC QTL ANALYSIS OF MAJOR DEPRESSIVE DISORDER102
T84. AN INVESTIGATION ON GENETIC MECHANISMS UNDER CLINICAL HETEROGENEITY IN SCHIZOPHRENIA101
F41. AMBER: ANTIDEPRESSANT MEDICATIONS: BIOLOGY, EXPOSURE AND RESPONSE97
T56. DIP2A, HIGHLY EXPRESSED GENE IN THE CEREBELLUM, IS ASSOCIATED WITH A WIDE RANGE OF PSYCHIATRIC SYMPTOMS (DELAYED SPEECH, AUTISM SPECTRUM DISORDER AND SPECIFIC LEARNING DISABILITIES)82
T13. GENETIC ASSOCIATIONS OF ICD-DERIVED PSYCHIATRIC DIAGNOSES WITH SELF-REPORTED MENTAL HEALTH PHENOTYPES IN THE UK BIOBANK73
F8. THE DEVELOPMENTAL LANDSCAPE OF NEUROPSYCHIATRIC GENOMICS IN AFRICA71
T78. GENE-ENVIRONMENT INTERACTION STUDY ON THE CORRELATES FOR PSYCHOTIC EXPERIENCES IN THE UK BIOBANK67
T100. CHILD SUBCORTICAL BRAIN VOLUMES: THE INTERACTION BETWEEN GENETIC RISK AND MATERNAL PSYCHOLOGICAL DISTRESS DURING PREGNANCY64
F97. DIFFERENTIAL EXPRESSION OF MICRORNAS UPON IN VITRO LITHIUM AND VALPROATE EXPOSURE TO BIPOLAR DISORDER PATIENTS-DERIVED LCLS63
41. CHARACTERIZING FUNCTIONAL CONVERGENCE OF COMMON POLYGENIC VARIATION IN NEUROPSYCHIATRIC DISORDER RISK GENES62
F75. PREDICTION OF TREATMENT-RESISTANT SCHIZOPHRENIA USING REAL-WORLD DATA AND MULTIMODAL ANALYTICAL TOOLS62
85. DETECTION OF PLACENTAL SCHIZOPHRENIA RISK GENES60
1. DEVELOPMENTAL TRAJECTORIES OF DNA METHYLATION IN NEURAL CELL POPULATIONS IN HUMAN CORTEX AND LINKS TO NEURODEVELOPMENTAL DISORDERS59
2. ENRICHMENT OF RARE, DAMAGING VARIANTS IN SCHIZOPHRENIA-RELATED GENES IN INTELLECTUAL DISABILITY PATIENTS WITH PSYCHOTIC DISORDERS54
T33. USING GENOMICS TO AID EARLY DIFFERENTIAL DIAGNOSIS BETWEEN BIPOLAR DISORDER AND MAJOR DEPRESSION51
T35. SHARED GENETIC LIABILITY FOR ALCOHOL CONSUMPTION, ALCOHOL PROBLEMS, AND SUICIDAL BEHAVIOR: EVALUATING THE ROLE OF IMPULSIVITY51
T59. A GENOME-WIDE ASSOCIATION STUDY OF EATING DISORDER SYMPTOMS BASED ON THE SCOFF QUESTIONNAIRE50
T67. ASSOCIATIONS BETWEEN METHYLATION AGE AND BRAIN AGE IN LATE ADOLESCENCE50
F48. INVESTIGATING POTENTIAL RELATIONSHIPS BETWEEN PIGMENTATION GENETICS AND PARKINSON'S DISEASE (PD)46
6. DE NOVO MUTATIONS IN BIPOLAR DISORDER IMPLICATE GENES INVOLVED IN NEURODEVELOPMENT AND IMMUNITY46
Society Calendar45
P.0511 The role of sex steroids and serotonin brain dynamics in perinatal mental health44
W101. EPIGENETIC PROFILES OF LATENT CLASSES FOR POLYSUBSTANCE USE DISORDER43
HOW PARTICIPATING IN CAMH'S PHARMACOGENETICS IMPACT STUDY CHANGED MY LIFE42
P.0320 Depression, anxiety, psychotic-like symptoms and addiction in adolescents and adults who do and do not use cannabis40
P.0753 Pharmacotherapy, treatment satisfaction and funcional impact among fibromyalgia patients: characterization of a Portuguese sample40
P.0260 Optimising a human induced pluripotent stem cell system to model the effects of il-6 on early neurodevelopment38
P.0325 Corneal endothelial morphology and thickness changes in children with attention-deficit hyperactivity disorder38
F7. THE ASSOCIATIONS BETWEEN EDUCATIONAL EXPERIENCES AND MENTAL HEALTH FROM CHILDHOOD TO YOUNG ADULTHOOD37
W64. FAMILY BASED ASSOCIATION AND LINKAGE ANALYSES OF FAMILIAL ADHD36
P.0426 Proof-of-concept study testing SOM3355 for the treatment of chorea symptoms in Huntington's disease33
POLYGENIC RISK SCORES FOR PROBLEMATIC SUBSTANCE USE IN ADOLESCENTS: AN ENIGMA-ADDICTION STUDY33
P.0632 The added value of cognitive behavioral therapy on quality of life in combination with pharmacotherapy in adults with ADHD33
P.0234 Optogenetic shift of mesolimbic dopamine to tonic pattern reduces reward-seeking behavior33
Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder33
0.072784900665283